Cargando…

The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure

Epicardial fat thickness is associated with cardiovascular disease. Mineralocorticoid receptor antagonist (MRA), a pharmaceutical treatment for CVD, was found to have an effect on adipose tissue. Our aim was to analyse the main epicardial fat genesis and inflammation-involved cell markers and their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Xiaoran, Almenglo, Cristina, Fernandez, Ángel Luis, Martínez-Cereijo, José Manuel, Iglesias-Alvarez, Diego, Duran-Muñoz, Darío, García-Caballero, Tomás, Gonzalez-Juanatey, Jose Ramón, Rodriguez-Mañero, Moises, Eiras, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027091/ https://www.ncbi.nlm.nih.gov/pubmed/35455943 http://dx.doi.org/10.3390/cells11081264

Ejemplares similares

Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue‐molecules and SGLT2i dapagliflozin
por: Almengló, Cristina, et al.
Publicado: (2022)

Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open‐heart surgery
por: Couselo‐Seijas, Marinela, et al.
Publicado: (2020)

The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation
por: López-Canoa, José Nicolás, et al.
Publicado: (2022)

Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
por: Salgado-Barreira, Angel, et al.
Publicado: (2023)

Clinical Profiling and Biomarkers for Post-Operative Atrial Fibrillation Prediction in Patients Undergoing Cardiac Surgery
por: Iglesias-Álvarez, Diego, et al.
Publicado: (2023)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
por: Duran, Jason M., et al.
Publicado: (2020)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Anti-Diabetogenic Properties of Mineralocorticoid Receptor Antagonists: Implications for Enhanced Safety and Efficacy of Post-Transplantation Pharmacotherapies
por: Ming, Yingzi, et al.
Publicado: (2019)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Myocardium Metabolism in Physiological and Pathophysiological States: Implications of Epicardial Adipose Tissue and Potential Therapeutic Targets
por: Gandoy-Fieiras, Nerea, et al.
Publicado: (2020)

Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
por: García-Vega, David, et al.
Publicado: (2022)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value
por: Almengló, Cristina, et al.
Publicado: (2021)

COVID-19 y tratamiento guiado con tests de diagnóstico bioquímicos y moleculares para reducir el daño cardiaco y la cardiotoxicidad
por: Eiras, Sonia, et al.
Publicado: (2020)

COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity
por: Eiras, Sonia, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Nutrients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in de novo heart failure patients
por: Agra, Rosa M, et al.
Publicado: (2018)

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
por: Trevisan, Marco, et al.
Publicado: (2018)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
por: Kapoor, Kapil G., et al.
Publicado: (2016)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists
por: Pérez-Gordillo, Felipe Luis, et al.
Publicado: (2023)

Omentin protects H9c2 cells against docetaxel cardiotoxicity
por: Lage, Ricardo, et al.
Publicado: (2019)

CD5L, Macrophage Apoptosis Inhibitor, Was Identified in Epicardial Fat-Secretome and Regulated by Isoproterenol From Patients With Heart Failure
por: Agra-Bermejo, Rosa M., et al.
Publicado: (2020)

Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure
por: Löfman, Ida, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
por: Berbenetz, Nicolas M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_muthjubaumurn7pc20jakahk2e